Medical drugs

China’s ascendence as a drug development powerhouse could threaten US biotechnology

A new wave of cheap weight-loss drugs heralds an existential crisis for the sin economy

Core earnings for the three months ended March rise to US$2.58 per share, while total revenue jumps 8% to US$15.3 billion

Beijing has equally begun to protect its own nascent databases, passing a biosecurity law in 2020

[WASHINGTON, DC] The Trump administration will impose tariffs of as much as 100 per cent on certain imported medicines, albeit with several major exemptions, a maneuver to pressure drugmakers to manuf...

One firm plans to make a semaglutide jab at a starting price of 1,290 rupees a month

The international health governance landscape is at a critical and precarious juncture

This underscores the US drugmaker’s push to diversify beyond its blockbuster drug

The funding will be directed towards the research and production of biologics and biosimilar medicines